For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
All Authors
AK

HCP Connect Contributor

Dr. Aditi Kulkarni

Dr. Aditi Kulkarni contributes neurology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.

Recent Drug Updates

21 total

Neurology

FDA Approves Lecanemab for Alzheimer: 27% Cognitive Decline Reduction

FDA approves lecanemab for Alzheimer: 27% cognitive decline reduction in early-stage patients, highlighting new treatment options.

May 14, 2026|3 min read|Via FDA

Neurology

FDA Approves Lecanemab for Alzheimer: Biweekly IV vs Weekly Subcutaneous Administration

FDA approves lecanemab for Alzheimer: biweekly IV vs weekly subcutaneous administration options.

May 14, 2026|3 min read|Via FDA

Neurology

FDA Approves Tolbrutinib for Progressive MS: New BTK Inhibitor in Treatment Algorithm

FDA approves tolbrutinib for progressive MS, offering a new BTK inhibitor option for treatment.

May 14, 2026|3 min read|Via WHO

Neurology

CGRP Inhibitors for Migraine Prevention: Comparing Erenumab, Fremanezumab, Atogepant, and Rimegepant

CGRP inhibitors for migraine prevention: comparing erenumab, fremanezumab, atogepant, and rimegepant for optimal patient outcomes.

May 14, 2026|3 min read|Via WHO

Neurology

FDA Approves Lecanemab Subcutaneous Autoinjector for Alzheimer: Weekly Home Administration vs Biweekly IV

Lecanemab subcutaneous autoinjector approved for Alzheimer's: weekly home administration vs biweekly IV.

May 12, 2026|3 min read|Via FDA

Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: Novel Treatment Algorithm for Seronegative Cases

Efgartigimod offers a new treatment algorithm for myasthenia gravis, reducing IgG levels and improving patient outcomes.

May 12, 2026|3 min read|Via WHO

Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: New Subcutaneous Formulation Enhances Patient Access

Efgartigimod approved for myasthenia gravis: new subcutaneous formulation enhances patient access and adherence.

May 9, 2026|3 min read|Via FDA

Neurology

FDA Approves Lecanemab for Alzheimer: Weekly Dosing Option Now Available

FDA approves lecanemab for Alzheimer: weekly dosing option now available for home administration.

May 8, 2026|2 min read|Via FDA

Neurology

FDA Grants Priority Review for Weekly Subcutaneous Lecanemab in Alzheimer’s Disease

FDA grants priority review for weekly subcutaneous lecanemab in Alzheimer’s disease, enhancing treatment accessibility.

May 7, 2026|3 min read|Via FDA

Neurology

FDA Approves Copper Histidinate for Menkes Disease: 78% Reduction in Mortality Risk

FDA approves copper histidinate for Menkes disease: 78% reduction in mortality risk for pediatric patients.

May 7, 2026|3 min read|Via FDA

Neurology

CGRP Inhibitors: Erenumab, Fremanezumab, and Galcanezumab for Migraine Prevention

CGRP inhibitors erenumab, fremanezumab, and galcanezumab reduce migraine frequency, offering new prevention options.

May 1, 2026|3 min read|Via WHO

Neurology

FDA Approves Zycubo for Menkes Disease: 78% Reduction in Mortality Risk

FDA approves Zycubo for Menkes disease: 78% reduction in mortality risk in pediatric patients.

May 1, 2026|3 min read|Via FDA

Neurology

FDA Approves Donanemab for Alzheimer: 27% Cognitive Decline Reduction

FDA approves donanemab for Alzheimer: 27% cognitive decline reduction in mild AD patients.

Apr 30, 2026|3 min read|Via FDA

Neurology

FDA Approves Atogepant for Episodic Migraine Prevention: 50% Reduction in Monthly Migraine Days

Atogepant (Qulipta) approved for episodic migraine prevention: 50% reduction in monthly migraine days.

Apr 29, 2026|3 min read|Via NEJM

Medical Research

Type 2 Diabetes Linked to Faster Chronic Disease Onset

New research reveals type 2 diabetes accelerates development of multiple chronic diseases, particularly in middle-aged adults, impacting patient outcomes and treatment plans.

Apr 23, 2026|4 min read|Via Medical Xpress

Medical Research

Emotional Eaters Less Likely to Lose Weight on GLP-1 Therapy

Research reveals individuals who overeat for emotional reasons may have reduced weight loss success with GLP-1 receptor agonists like Ozempic.

Apr 19, 2026|4 min read|Via Medical Xpress

Healthcare Business

Reduce Mental Fatigue in Hearing Loss Patients by 30%

Discover how addressing hearing loss can improve mental health outcomes, reducing social isolation, anxiety, and depression in patients.

Apr 18, 2026|7 min read|Via American Journal Managed Care

Neurology

Boost Neurology Dept Efficiency with Effective Vice Chair Roles

Discover how evolving vice chair responsibilities can enhance neurology department leadership, faculty engagement, and alignment with institutional goals.

Apr 4, 2026|2 min read|Via Neurology Live

Health Information

Accurate RA Diagnosis in Less Time

Learn how lab tests and imaging help doctors diagnose rheumatoid arthritis quickly and accurately, reducing diagnostic time and improving patient outcomes.

Apr 2, 2026|6 min read|Via MedlinePlus

Medical Devices

Boost Breast Cancer Survival Rates with Latest Treatments

Discover how advances in breast cancer treatment are improving patient outcomes and survival rates, offering new hope for individuals diagnosed with the disease.

Mar 30, 2026|6 min read|Via Medical Device News Magazine

Medical Research

FDA May Drop Expert Reviews, Impacting Drug Approval

Proposed FDA policy change could reduce public scrutiny of new drug approvals, what it means for physicians and patient care decisions.

Mar 24, 2026|7 min read|Via Medical Xpress
Dr. Aditi Kulkarni | HCP Connect Authors | HCP Connect